Oramed

failure crash no fail rocket cancelled end

Biotech

Oramed’s oral insulin flunks phase 3 diabetes test

The biotech outlined plans to stop development in type 2 diabetes and sent its share price tumbling in the process.

Nick Paul Taylor Jan 12, 2023 6:30am

ruins

Oramed data 'paint an exciting picture' in rocky NASH landscape

Sep 13, 2022 11:20am

Tablets

Oramed hits midstage target in oral insulin trial

May 18, 2016 8:37am